Editing Ribavirin (section)

== Adverse effects ==
{{Main list|List of adverse effects of ribavirin}}

The medication has two FDA "black box" warnings: One raises concerns that use before or during pregnancy by either sex may result in birth defects in the baby, and the other is regarding the risk of red blood cell breakdown.<ref>{{cite web|title=Copedgus|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf|website=FDA.gov|access-date=16 April 2017|url-status=live|archive-url=https://web.archive.org/web/20141103185016/http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf|archive-date=3 November 2014}}</ref>

Ribavirin should not be given with [[zidovudine]] because of the increased risk of anemia;<ref>{{cite journal | vauthors = Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS | title = Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons | journal = Journal of Viral Hepatitis | volume = 13 | issue = 10 | pages = 683–689 | date = October 2006 | pmid = 16970600 | doi = 10.1111/j.1365-2893.2006.00749.x | s2cid = 21474337 }}</ref> concurrent use with [[didanosine]] should likewise be avoided because of an increased risk of [[mitochondrial toxicity]].<ref>{{cite journal | vauthors = Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C | title = Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy | journal = Journal of Acquired Immune Deficiency Syndromes | volume = 40 | issue = 1 | pages = 47–52 | date = September 2005 | pmid = 16123681 | doi = 10.1097/01.qai.0000174649.51084.46 | s2cid = 9364536 | collaboration = Anrs Hc02-Ribavic Study Team | doi-access = free }}</ref>